Psyence Biomedical Signs Manufacturing Services Agreement With DEA-Registered Benuvia For Planned U.S. Manufacture Of Pharmaceutical-Grade Ibogaine Active Pharmaceutical Ingredient

Psyence Biomedical Unit TIRC Signs Binding Term Sheet With Psyence Labs For An Exclusive License, Supply And Wholesale Distribution Arrangement For Psylabs’ Pharmaceutical-Grade Ibogaine In The U.S.

The term sheet is binding on the parties and is to be superseded by a definitive agreement, which the parties have agreed to conclude on or before November 30, 2026; if a definitive agreement is not signed by that date,

Psyence Biomedical shares are trading higher after the company announced a cash investment of up to $5 million in Psyence Labs.

Psyence Biomedical Agrees To Make Cash Investment Of Up To $5M In Psyence Labs

Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchangeHighlightsThe Company is actively advancing plans for a potential ibogaine clinical trial